Jiskyn (Bendamustine Hydrochloride)

Bendamustine is an alkylating agent that creates covalent bonds between DNA strands, preventing DNA replication and transcription. This DNA damage triggers cell‑cycle arrest and apoptosis, leading to selective death of rapidly dividing malignant lymphoid cells.

The dosing regimen for Jiskyn is individualized and determined by the prescribing oncologist based on the patient’s disease type, stage, body surface area, and overall health. Specific dose calculations are not provided here.

Safety of bendamustine during pregnancy and lactation has not been established. It is classified as contraindicated for pregnant or nursing women because of potential fetal harm and unknown excretion in breast milk. Effective contraception is recommended.

To request Jiskyn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Bendamustine offers a distinct alkylating mechanism compared with agents such as chlorambucil or rituximab‑based regimens. It provides higher response rates in certain CLL and NHL subtypes, but its toxicity profile—particularly myelosuppression—requires careful monitoring, whereas some alternatives may have different side‑effect spectra.

Jiskyn must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Jiskyn is supplied as a sterile solution for injection and is administered intravenously by a qualified healthcare professional. The infusion is typically given over a defined period, often 30–60 minutes, under close clinical supervision.

The most serious risks include severe infections due to neutropenia, profound thrombocytopenia leading to bleeding, and the rare possibility of secondary malignancies. Continuous monitoring of blood counts and prompt management of febrile episodes are essential to mitigate these risks.

Jiskyn should be avoided in patients with known hypersensitivity to bendamustine or any formulation component, in those with uncontrolled severe organ dysfunction, and in pregnant or breastfeeding women. Caution is also advised for individuals with active infections or significant bone‑marrow failure.